Ablation of serum response factor in dopaminergic neurons exacerbates susceptibility towards MPTP-induced oxidative stress

European Journal of Neuroscience

Volumn 35, Issue 5, 2012, Pages 735-741

  Rieker, Claus ^a,b   Schober, Andreas ^c   Bilbao, Ainhoa ^d   Schütz, Günther ^a   Parkitna, Jan Rodriguez ^a,e  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^e INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Cre loxP knockout mouse; Parkinsonism

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; PROTEIN BCL 2; SERUM RESPONSE FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL POPULATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY CHAIN; SUBSTANTIA NIGRA; TRANSCRIPTION REGULATION; VENTRAL TEGMENTUM;

ANIMALS; DISEASE SUSCEPTIBILITY; DOPAMINERGIC NEURONS; GENETIC PREDISPOSITION TO DISEASE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MPTP POISONING; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; SERUM RESPONSE FACTOR; SUBSTANTIA NIGRA;

EID: 84857994636     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2012.08003.x     Document Type: Article

References (43)

1. Abou-Sleiman, P.M., Muqit, M.M. & Wood, N.W. (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci., 7, 207-219.
2. Bier, E. (2006) Antioxidants put Parkinson flies back in the PINK. Proc. Natl Acad. Sci. USA, 103, 13269-13270.
3. Burke, R.E. (2007) Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol. Ther., 114, 261-277.
4. Chan, C.S., Guzman, J.N., Ilijic, E., Mercer, J.N., Rick, C., Tkatch, T., Meredith, G.E. & Surmeier, D.J. (2007) 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature, 447, 1081-1086.
5. Chan, C.S., Gertler, T.S. & Surmeier, D.J. (2009) Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci., 32, 249-256.
6. Chang, S.H., Poser, S. & Xia, Z. (2004) A novel role for serum response factor in neuronal survival. J. Neurosci., 24, 2277-2285.
7. Dauer, W. & Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron, 39, 889-909.
8. Farrer, M., Stone, J., Mata, I.F., Lincoln, S., Kachergus, J., Hulihan, M., Strain, K.J. & Maraganore, D.M. (2005) LRRK2 mutations in Parkinson disease. Neurology, 65, 738-740.
9. Finkel, T. (2005) Opinion: radical medicine: treating ageing to cure disease. Nat. Rev. Mol. Cell Biol., 6, 971-976.
10. Gainetdinov, R.R., Jones, S.R. & Caron, M.G. (1999) Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol. Psychiatry, 46, 303-311.
11. Gloeckner, C.J., Schumacher, A., Boldt, K. & Ueffing, M. (2009) The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J. Neurochem., 109, 959-968.
12. Howells, D.W., Porritt, M.J., Wong, J.Y., Batchelor, P.E., Kalnins, R., Hughes, A.J. & Donnan, G.A. (2000) Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol., 166, 127-135.
13. Hsu, C.H., Chan, D., Greggio, E., Saha, S., Guillily, M.D., Ferree, A., Raghavan, K., Shen, G.C., Segal, L., Ryu, H., Cookson, M.R. & Wolozin, B. (2010) MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J. Neurochem., 112, 1593-1604.
14. Jackson-Lewis, V. & Przedborski, S. (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc., 2, 141-151.
15. Kish, S.J., Shannak, K. & Hornykiewicz, O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med., 318, 876-880.
16. Knoll, B. & Nordheim, A. (2009) Functional versatility of transcription factors in the nervous system: the SRF paradigm. Trends Neurosci., 32, 432-442.
17. Kroemer, G., Galluzzi, L. & Brenner, C. (2007) Mitochondrial membrane permeabilization in cell death. Physiol. Rev., 87, 99-163.
18. Lin, M.T. & Beal, M.F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443, 787-795.
19. Liss, B., Haeckel, O., Wildmann, J., Miki, T., Seino, S. & Roeper, J. (2005) K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci., 8, 1742-1751.
20. Luxenburg, C., Pasolli, H.A., Williams, S.E. & Fuchs, E. (2011) Developmental roles for Srf, cortical cytoskeleton and cell shape in epidermal spindle orientation. Nat. Cell Biol., 13, 203-214.
21. Mantamadiotis, T., Lemberger, T., Bleckmann, S.C., Kern, H., Kretz, O., Martin Villalba, A., Tronche, F., Kellendonk, C., Gau, D., Kapfhammer, J., Otto, C., Schmid, W. & Schutz, G. (2002) Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet., 31, 47-54.
22. Mocchetti, I., Bachis, A., Nosheny, R.L. & Tanda, G. (2007) Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons. Neurotox. Res., 12, 135-143.
23. Moore, D.J., West, A.B., Dawson, V.L. & Dawson, T.M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci., 28, 57-87.
24. Parlato, R., Rieker, C., Turiault, M., Tronche, F. & Schutz, G. (2006) Survival of DA neurons is independent of CREM upregulation in absence of CREB. Genesis, 44, 454-464.
25. Porritt, M.J., Batchelor, P.E. & Howells, D.W. (2005) Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp. Neurol., 192, 226-234.
26. Rieker, C., Engblom, D., Kreiner, G., Domanskyi, A., Schober, A., Stotz, S., Neumann, M., Yuan, X., Grummt, I., Schutz, G. & Parlato, R. (2011) Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling. J. Neurosci., 31, 453-460.
27. Rodriguez Parkitna, J., Bilbao, A., Rieker, C., Engblom, D., Piechota, M., Nordheim, A., Spanagel, R. & Schutz, G. (2010) Loss of the serum response factor in the dopamine system leads to hyperactivity. FASEB J., 24, 2427-2435.
28. Schober, A. (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res., 318, 215-224.
29. Schober, A., Peterziel, H., von Bartheld, C.S., Simon, H., Krieglstein, K. & Unsicker, K. (2007) GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action. Neurobiol. Dis., 25, 378-391.
30. Schratt, G., Weinhold, B., Lundberg, A.S., Schuck, S., Berger, J., Schwarz, H., Weinberg, R.A., Ruther, U. & Nordheim, A. (2001) Serum response factor is required for immediate-early gene activation yet is dispensable for proliferation of embryonic stem cells. Mol. Cell. Biol., 21, 2933-2943.
31. Schratt, G., Philippar, U., Hockemeyer, D., Schwarz, H., Alberti, S. & Nordheim, A. (2004) SRF regulates Bcl-2 expression and promotes cell survival during murine embryonic development. EMBO J., 23, 1834-1844.
32. Simunovic, F., Yi, M., Wang, Y., Macey, L., Brown, L.T., Krichevsky, A.M., Andersen, S.L., Stephens, R.M., Benes, F.M. & Sonntag, K.C. (2009) Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain, 132, 1795-1809.
33. Spielewoy, C., Biala, G., Roubert, C., Hamon, M., Betancur, C. & Giros, B. (2001) Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology (Berl), 159, 2-9.
34. Sulzer, D. (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci., 30, 244-250.
35. Sutherland, G.T., Matigian, N.A., Chalk, A.M., Anderson, M.J., Silburn, P.A., Mackay-Sim, A., Wells, C.A. & Mellick, G.D. (2009) A cross-study transcriptional analysis of Parkinson's disease. PLoS ONE, 4, e4955.
36. Tan, E.K. (2007) The role of common genetic risk variants in Parkinson disease. Clin. Genet., 72, 387-393.
37. Vyas, I., Heikkila, R.E. & Nicklas, W.J. (1986) Studies on the neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J. Neurochem., 46, 1501-1507.
38. West, M.J. (1993) New stereological methods for counting neurons. Neurobiol. Aging, 14, 275-285.
39. Wiebel, F.F., Rennekampff, V., Vintersten, K. & Nordheim, A. (2002) Generation of mice carrying conditional knockout alleles for the transcription factor SRF. Genesis, 32, 124-126.
40. Xiong, Y., Coombes, C.E., Kilaru, A., Li, X., Gitler, A.D., Bowers, W.J., Dawson, V.L., Dawson, T.M. & Moore, D.J. (2010) GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet., 6, e1000902.
41. Yu, W., Gwinn, M., Clyne, M., Yesupriya, A. & Khoury, M.J. (2008) A navigator for human genome epidemiology. Nat. Genet., 40, 124-125.
42. Zhang, H.M., Li, L., Papadopoulou, N., Hodgson, G., Evans, E., Galbraith, M., Dear, M., Vougier, S., Saxton, J. & Shaw, P.E. (2008) Mitogen-induced recruitment of ERK and MSK to SRE promoter complexes by ternary complex factor Elk-1. Nucleic Acids Res., 36, 2594-2607.
43. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., Stoessl, A.J., Pfeiffer, R.F., Patenge, N., Carbajal, I.C., Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D.W., Meitinger, T., Strom, T.M., Wszolek, Z.K. & Gasser, T. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601-607.